Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis

Intrahepatic cholangiocarcinoma (iCCA) is a deadly disease with rising incidence and few treatment options. An altered expression and/or activation of NOTCH1–3 receptors has been shown to play a role in iCCA development and progression. In this study, we established a new CCA patient-derived xenogra...

Descripción completa

Detalles Bibliográficos
Autores principales: Mancarella, Serena, Serino, Grazia, Dituri, Francesco, Cigliano, Antonio, Ribback, Silvia, Wang, Jingxiao, Chen, Xin, Calvisi, Diego F., Giannelli, Gianluigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370218/
https://www.ncbi.nlm.nih.gov/pubmed/32042099
http://dx.doi.org/10.1038/s41418-020-0505-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370218/
https://www.ncbi.nlm.nih.gov/pubmed/32042099
http://dx.doi.org/10.1038/s41418-020-0505-4

Ejemplares similares